CA-9在预测乳腺癌新辅助化疗EC方案敏感性中的作用  

Role of CA-9 in predicting susceptibility to neoadjuvant chemotherapy EC regimen in breast cancer

作　　者：杨怀才 余文洁 赖兆泳 骆国英 胡万能 宋超 Yang Huai-Cai;Yu Wen-Jie;Lai Zhao-Yong(Breast Department of Qingyuan Maternal and Child Health Hospital,Qingyuan 511515,Guangdong,China)

机构地区：[1]清远市妇幼保健院乳腺科,广东清远511515 [2]清远市妇幼保健院病理科,广东清远511515

出　　处：《吉林医学》2025年第4期787-791,共5页Jilin Medical Journal

基　　金：清远市社会发展领域科技计划项目[项目编号:190823094564033]。

摘　　要：目的:探讨碳酸酐酶-9(CA-9)在预测乳腺癌患者新辅助化疗EC方案敏感性中的作用。方法:回顾性选取2019年1月~2023年6月清远市妇幼保健院收治的82例接受新辅助化疗EC方案乳腺癌患者为研究对象,收集患者治疗前病灶组织及正常癌旁组织标本,对比病灶组织和癌旁组织CA-9表达,分析EC方案敏感性、无瘤生存率、总生存率与CA-9表达的关系。结果:82例乳腺癌患者病灶组织CA-9低表达率26.83%(11/82),高表达率73.17%(60/82);正常癌旁组织低表达率82.93%(68/82),高表达率17.07%(14/82),差异均有统计意义(P<0.05)。CA-9表达与患者年龄、月经状况、肿瘤大小无关(P>0.05),与组织病理分级、肿瘤分期、淋巴结转移情况有关(P<0.05)。CA-9低表达患者EC方案新辅助化疗总有效率为95.94%(21/22),CA-9高表达患者EC方案新辅助化疗总有效率为68.33%(41/60),差异有统计学意义(P<0.05)。CA-9低表达患者无瘤生存率、总生存率分别为81.80%、86.40%,高于CA-9高表达患者的66.70%、70.00%,差异均有统计学意义(P<0.05)。结论:乳腺癌病灶组织CA-9表达与EC方案化疗敏感性相关,CA-9高表达提示患者EC方案新辅助化疗敏感性降低及不良生存预后。Objective To investigate the role of carbonic anhydrase-9(CA-9)in predicting the sensitivity of neoadjuvant chemotherapy EC regimen for breast cancer.Methods The study's subjects were 82 breast cancer patients who were hospitalized to Qingyuan Maternal and Child Health Hospital between January 2019 and June 2023.The Neoadjuvant Chemotherapy EC regimen was prescribed to them.Samples of focal tissues and normal paracancer tissues were collected before treatment,and CA-9 expression was compared between focal tissues and paracancer tissues.The relationship between EC protocol sensitivity,tumor-free survival rate,overall survival rate,and CA-9 expression was analyzed.Results In 82 cases of breast cancer,the low expression rate of CA-49 in lesion tissues was 26.83%(11/82),the high expression rate was 73.17%(60/82),the low expression rate was 82.93%(68/82),the high expression rate was 17.07%(14/82),and the difference was statistically significant(P<0.05).CA-9 expression was not correlated with age,menstrual status,and tumor size(P>0.05),but was correlated with histopathologic grade,tumor stage,and lymph node metastasis(P<0.05).The total effective rate of neoadjuvant chemotherapy EC was 95.94%(21/22)in patients with low expression of CA-9,and 68.33%(41/60)in patients with high expression of CA-9,the difference was statistically significant(P<0.05).The tumor-free and overall survival rates of patients with low CA-9 expression were 81.80%and 86.40%,respectively,which were higher than those of patients with high CA-9 expression(66.70%and 70.00%,P<0.05).Conclusions The expression of CA-9 in breast cancer foci is related to the sensitivity to chemotherapy of EC regimen,and the high expression of CA-9 indicates decreased sensitivity to chemotherapy and poor survival prognosis.

关 键 词：碳酸酐酶-9 乳腺癌 新辅助化疗 EC方案 敏感性 

分 类 号：R737.9[医药卫生—肿瘤]